Latest Share Chat

REMOVE ADS

Glaxosmithkline Regulatory News (GSK)

Glaxosmithkline Information

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes

Get Live Data

1,972.50 22.50 (1.15%)

Bid:

1,971.00

Ask:

1,971.50

Spread: 0.50 (0.025%)

Market Cap: £79.05b

Last checked at -

Intraday Glaxosmithkline Share Chart

REMOVE ADS

Director/PDMR Shareholding

15 Feb 2023 16:04

RNS Number : 0567Q

GSK PLC

15 February 2023

GSK plc (the 'Company')

Vesting of Deferred Bonus Awards under the Deferred Annual Bonus Plan and Sale of Ordinary Shares

This notification sets out the vesting details for Persons Discharging Managerial Responsibilities ('PDMRs') of Deferred Bonus Awards over Ordinary Shares made in 2020 under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan ('DABP') and subsequent sale of Ordinary Shares to meet tax liabilities. In accordance with the shareholder approved 2017 Remuneration Policy and the DABP rules, the awards comprised a mandatory bonus deferral only. The three-year restricted period for the awards commenced on 14 February 2020 and ended on 14 February 2023. Dividends accrued on the awards during the restricted period. The awards were granted in 2020 as nil-cost options over Ordinary Shares.

The closing price of Ordinary Shares of GSK plc on 14 February 2023 was £14.70.

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms E Walmsley
b)	Position/status	Chief Executive Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	60,707

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-02-14
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms E Walmsley
b)	Position/status	Chief Executive Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.8730	28,576

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-02-14
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr I Mackay
b)	Position/status	Chief Financial Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	40,985

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-02-14
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr I Mackay
b)	Position/status	Chief Financial Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.8887	19,292

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-02-14
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms D Conrad
b)	Position/status	Chief People Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	7,893

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-02-14
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms D Conrad
b)	Position/status	Chief People Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.8743	4,240

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-02-14
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr J Ford
b)	Position/status	SVP and Group General Counsel, Legal and Compliance
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	11,259

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-02-14
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr J Ford
b)	Position/status	SVP and Group General Counsel, Legal and Compliance
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.8628	5,305

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-02-14
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms S Jackson
b)	Position/status	SVP, Global Communications and CEO Office
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	4,796

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-02-14
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms S Jackson
b)	Position/status	SVP, Global Communications and CEO Office
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.8804	2,263

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-02-14
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr L Miels
b)	Position/status	Chief Commercial Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	18,375

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-02-14
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr L Miels
b)	Position/status	Chief Commercial Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.8830	1,171

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-02-14
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr D Redfern
b)	Position/status	President Corporate Development
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	13,471

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-02-14
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr D Redfern
b)	Position/status	President Corporate Development
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.8750	6,348

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-02-14
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr R Simard
b)	Position/status	President, Global Supply Chain
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	9,539

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-02-14
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr R Simard
b)	Position/status	President, Global Supply Chain
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.8756	4,500

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-02-14
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr P Thomson
b)	Position/status	President, Global Affairs
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The vesting of an award in the form of a nil-cost option over Ordinary Shares granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan and the subsequent exercise of the nil-cost option
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	7,779

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-02-14
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr P Thomson
b)	Position/status	President, Global Affairs
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on the exercise of a nil-cost option award granted in 2020 under the Company's 2017 Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£14.8772	3,669

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2023-02-14
f)	Place of the transaction	London Stock Exchange (XLON)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHSFFFMIEDSESE

Date		Source	Headline
18th Nov 2025	3:30 pm	RNS	Director/PDMR Shareholding
18th Nov 2025	7:00 am	RNS	Transaction in Own Shares
17th Nov 2025	7:00 am	RNS	Transaction in Own Shares
14th Nov 2025	7:00 am	RNS	Transaction in Own Shares
13th Nov 2025	3:30 pm	RNS	Director/PDMR Shareholding
13th Nov 2025	7:00 am	RNS	Transaction in Own Shares
12th Nov 2025	3:30 pm	RNS	Block listing Interim Review
12th Nov 2025	7:00 am	RNS	Transaction in Own Shares
11th Nov 2025	7:00 am	RNS	Transaction in Own Shares
10th Nov 2025	3:00 pm	RNS	GSK publishes provisional dividend dates
10th Nov 2025	7:00 am	RNS	Transaction in Own Shares
7th Nov 2025	7:00 am	RNS	Transaction in Own Shares
6th Nov 2025	7:00 am	RNS	Transaction in Own Shares
5th Nov 2025	7:00 am	RNS	Transaction in Own Shares
4th Nov 2025	7:00 am	RNS	Transaction in Own Shares
3rd Nov 2025	3:00 pm	RNS	Total Voting Rights
3rd Nov 2025	7:00 am	RNS	Transaction in Own Shares
31st Oct 2025	7:00 am	RNS	Transaction in Own Shares
30th Oct 2025	3:30 pm	RNS	Director/PDMR Shareholding
30th Oct 2025	7:00 am	RNS	Transaction in Own Shares
29th Oct 2025	7:05 am	RNS	Transaction in Own Shares
29th Oct 2025	7:00 am	RNS	3rd Quarter Results
28th Oct 2025	7:00 am	RNS	Transaction in Own Shares
28th Oct 2025	7:00 am	RNS	GSK ADC gets orphan drug designation in the EU
27th Oct 2025	7:00 am	RNS	Transaction in Own Shares
24th Oct 2025	7:00 am	RNS	Blenrep approved by US FDA in multiple myeloma
24th Oct 2025	7:00 am	RNS	Transaction in Own Shares
23rd Oct 2025	7:00 am	RNS	Transaction in Own Shares
22nd Oct 2025	7:05 am	RNS	Positive data for low carbon version Ventolin MDI
22nd Oct 2025	7:00 am	RNS	Transaction in Own Shares
22nd Oct 2025	7:00 am	RNS	Latozinemab data read out
21st Oct 2025	7:05 am	RNS	Positive CHMP Opinion for GSK on Shingrix PFS
21st Oct 2025	7:00 am	RNS	Transaction in Own Shares
21st Oct 2025	7:00 am	RNS	GSK share positive Ph3 data on tebipenem HBr
20th Oct 2025	7:00 am	RNS	Transaction in Own Shares
17th Oct 2025	7:00 am	RNS	Transaction in Own Shares
16th Oct 2025	3:30 pm	RNS	Director/PDMR Shareholding
16th Oct 2025	7:00 am	RNS	Transaction in Own Shares
15th Oct 2025	3:30 pm	RNS	Director/PDMR Shareholding
15th Oct 2025	7:00 am	RNS	Transaction in Own Shares
14th Oct 2025	7:00 am	RNS	GSK receives expanded Shingrix approval in China
14th Oct 2025	7:00 am	RNS	Transaction in Own Shares
13th Oct 2025	3:30 pm	RNS	Director/PDMR Shareholding
13th Oct 2025	7:00 am	RNS	Transaction in Own Shares
10th Oct 2025	3:30 pm	RNS	Director/PDMR Shareholding
10th Oct 2025	7:00 am	RNS	Transaction in Own Shares
9th Oct 2025	7:00 am	RNS	Transaction in Own Shares
8th Oct 2025	7:00 am	RNS	Transaction in Own Shares
7th Oct 2025	7:00 am	RNS	Transaction in Own Shares
6th Oct 2025	7:00 am	RNS	Transaction in Own Shares

Latest Share Chat

Glaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

Intraday Glaxosmithkline Share Chart

Director/PDMR Shareholding

Please enter at least 2 characters

No results found

Search results

Recently viewed

Trending